68Ga-FAPI-46 Dosimetry Summary of Mean Absorbed and Effective Doses Using OLINDA/EXM
| Organ | Dose per injected activity (mGy/MBq) | Effective dose per injected activity (mSv/MBq) |
| Adrenals | 5.60E−03 (8.12E−04) | 2.80E−05 (4.04E−06) |
| Brain | 4.59E−03 (6.12E−04) | 2.29E−05 (3.06E−06) |
| Breasts | 4.55E−03 (6.47E−04) | 2.28E−04 (3.23E−05) |
| Gallbladder wall | 5.62E−03 (8.53E−04) | — |
| Lower large intestine wall | 5.72E−03 (6.96E−04) | 6.86E−04 (8.33E−05) |
| Small intestine | 5.48E−03 (6.37E−04) | 2.74E−05 (3.20E−06) |
| Stomach wall | 5.32E−03 (7.25E−04) | 6.38E−04 (8.69E−05) |
| Upper large intestine wall | 5.47E−03 (6.97E−04) | 2.74E−05 (3.50E−06) |
| Heart wall | 1.11E−02 (1.26E−03) | — |
| Kidneys | 1.60E−02 (4.60E−03) | 7.98E−05 (2.29E−05) |
| Liver | 1.01E−02 (7.96E−03) | 5.05E−04 (4.00E−04) |
| Lungs | 5.02E−03 (7.09E−04) | 6.02E−04 (8.48E−05) |
| Muscle | 4.96E−03 (6.54E−04) | 2.48E−05 (3.27E−06) |
| Ovaries | 5.76E−03 (6.91E−04) | 1.15E−03 (1.38E−04) |
| Pancreas | 5.69E−03 (8.49E−04) | 2.84E−05 (4.24E−06) |
| Red marrow | 7.08E−03 (1.00E−03) | 8.49E−04 (1.20E−04) |
| Osteogenic cells | 9.38E−03 (1.30E−03) | 9.38E−05 (1.30E−05) |
| Skin | 4.41E−03 (6.33E−04) | 4.41E−05 (6.33E−06) |
| Spleen | 6.96E−03 (2.76E−03) | 3.48E−05 (1.39E−05) |
| Testes | 4.88E−03 (6.69E−04) | 1.15E−03 (1.38E−04) |
| Thymus | 5.10E−03 (6.40E−04) | 2.55E−05 (3.21E−06) |
| Thyroid | 4.84E−03 (5.72E−04) | 2.42E−04 (2.85E−05) |
| Urinary bladder wall | 4.83E−02 (8.55E−03) | 2.41E−03 (4.27E−04) |
| Uterus | 9.54E−03 (5.36E−03) | 4.76E−05 (2.67E−05) |
| Total body | 5.82E−03 (1.18E−03) | 7.80E−03 (1.31E−03) |
| Total body dose for 200 MBq | 1.16 mGy (0.24 mGy) | 1.56 mSv (0.26 mSv) |
Data are mean followed by SD in parentheses for 6 patients. Effective doses in ovaries and testes are equivalent because of use of hermaphroditic adult phantom weighting. Gallbladder wall and heart wall effective doses are not available based on ICRP radiation weighting factors. Nonpooled OLINDA/EXM reports, including β and photon contribution to total dose, are available in Supplemental Table 3.